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ABSTRACT
Using syngeneic Wistar-Lewis rats as the experimental subject, the
spontaneously arising renal adenocarcinoma of the clear cell type is
implanted under the renal capsule of the rat's left kidney while the
right kidney is used as a control. In one week intervals from three
weeks to a maximum of six weeks post implantation, a polymer casting
procedure(Shah, 1983; Babayan, Nelson, D'Amico, 1985) is employed to
create a plastic replica of the kidney-tumor microvasculature. The
plastic cast is analyzed to test the hypothesis that if a tumor engulfs
some fraction of its own vasculature as it grows, it leaves beneath its
expanding surface a fraction of the vasculature which may become open
ended. This open vessel system could provide a mechanical pathway for
tumor cells detached from the primary growth to travel into the main
circulatory system where they may be potentially involved in metastases.
An understanding of this pathway could help explain how the proliferation
of secondary growths at the site of the target tissue can be initiated in
the metastatic process.
In this investigation the use of thrombin as both a tumor growth
inhibitor and anti-metastatic agent is studied using two transplantable
renal tumor systems, adenocarcinoma(White, 1980) and rhabdomyo-
sarcoma(Barendsen, 1970) in the syngeneic Wistar-Lewis and Wag-Rij rats
respectively. From studies of tumor implantation on renal systems
(Babayan, Nelson;1984) it is shown that renal adenocarcinoma metastasizes
to the lung at eight weeks post implantation leading to animal death in
ten weeks due to the lethal effects of the lung metastases. Likewise,
the rhabdomyosarcoma metastasizes to the lung at seven weeks post
implantation leading to a similiar lethality in the animal.
The administration of one bolus injection of thrombin to the tumor
necrotic region at six weeks post-implantation(pre-metastatic) prolongs
the time to metastasis to approximately twenty weeks post-
implantation(or roughly double the life expectancy following tumor
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implantation) depending bn the-tumor diameter at the time the thrombin is
delivered. In addition, the growth rate of the primary tumor is
considerably decreased probabley due to vascular thrombosis of the tumor
vasculature leading to increased ischemia and subsequent tumor necrosis.
The results of the morphological examination and the success of the
thrombin therapy provide evidence for the existence of a radially
directed open vessel pathway in the metastatic process. From the
results of the students t-test on the morphological data one can assert
on a statistical basis with at least 95%(p < 0.05) certainity that inward
directed radial tumor vasculature exists. Two classes of these inward
radial tumor vessels are found: Class 1 consists of vessels that are not
active mitotically but are open-ended; Class 2 consists of vessels that
are active mitotically (i.e. growing) but are closed-ended; indicating
the growth of new tumor vasculature. Class 1 tumor vessels may provide
the entrance into which thrombin can permeate and fill the entire tumor
parenchyma resulting in both tumor toxic and anti-metastatic effects.
Thesis Supervisor: Professor Alan C. Nelson
Title: Associate Professor of Nuclear Engineering and the
Whitaker College of Health, Sciences, Technology and
Management
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1. INTRODUCTION and BACKGROUND
1.1 Background
For the most part, cancer starts as a localized proliferation of
cells arising from a single cell within a region of transformed cells.
As cell proliferation at the origin continues, there is often an increase
in the volume of the local proliferating cell mass and a consequent rise
in local tissue pressures. Microscopically, and often visually with
pigmented tumors clinically, one can observe that around the central mass
of proliferating cells, there are extensions of these cells that develop
in the cracks and crevices of the surrounding tissue. They dissect
along the tissue planes, may erode into vascular or lymphatic channels
and may extend for considerable distances while maintaining continuity
with the initial cell mass. Often, however, such extensions are
recognized only by the secondary effects, such as fibrosis, produced by
the migrating cells. Uniformity in extension generally does not exist,
since the boundaries are quite irregular in both lateral and depth
penetration with superficial cancers, and in size, shape, and extent with
central growths(Poste, 1977).
The tumor cell extensions at any given time may be more widespread
than clinical examination can determine, and thus the surgeon is faced
with the possibility of incomplete excision. The initial tumor together
'14'
with the probable area of invasion, must be excised. Removal of too much
tissue generally increases morbidity; yet removal of too little may lead
to local recurrence, which may be increasingly difficult to
treat(Kleinerman, 1974).
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1.2 Tumor Formation and Angiogenesis
Cancer cells are motile, have decreased mutual adhesiveness,
reduced contact inhibition, and can elaborate through tissues. Also,
they can secrete a compound called "tumor angiogenesis factor" (TAF)
which has been recently purified by Folkman(Folkman, 1985). Attempts to
uncover the mechanisms of angiogenesis have revealed the following:
(a) Angiogenesis itself is a multi-stage process in some ways
analogous to blood coagulation and
(b) the induction of neovascularization is not unique to tumors but is
associated with a variety of physiological and pathological
processes such as wound healing, maturation of the corpus luteum,
chronic inflammation, and delayed hypersensitivity.
In physiologic situations, as for example development of the corpus
luteum, angiogenesis seems to be necessary for completion of the process
and subsides or is turned off once the process is completed. In certain
pathologic states that are not malignant, angiogenesis is abnormally
prolonged although self-limiting. Examples are pyogenic granuloma,
keloid formation, or retrolental fibroplasia. By contrast, angiogenesis
in malignancy is not self-limiting. Once tumor-induced angiogenesis is
turned on, it continues indefinitely until all of the tumor is eradicated
or the host dies(Folkman, 1976).
'16'
The actual process by which new capillaries grow in response to a
tumor does, however, appear to be remarkably similiar to the capillary
proliferation associated with non-malignant angiogenesis. Common to all
forms of angiogenesis is a general pattern of response by the capillary
endothelial cell. The release of TAF has been shown to cause capillary
endothelial cells to grow in a manner that directs capillary growth
towards the tumor(Folkman, 1975). Continuous vascularization of the
tumor increases the supply of nutrients available for tumor growth.
Cancer cells can migrate, lose connection with the parent growth, and
enter the bloodstream. Even though the mere presence of malignant cells
in the blood is not diagnostic for metastasis(Salsbury, 1975), the fact
that cancer cells do circulate in the bloodstream, specifically during
surgery, is thought to contribute to the likelihood of metastasis.
Also, it is important to note that past experiments(Folkman, Langer,
etc..) imply that whatever the angiogeneic stimulus, it must be
continually present to maintain newly formed vessels. Removal of an
angiogenic stimulus is followed in one to two days by changes in the
endothelial cells located at the distal tips or loops of a new capillary
vessel. Mitochondria swell and some cells become thin and develop
fenestrations that may not be seen in healthy, non-regressing vessels.
Endothelial cells seperate, permitting escape of erythrocytes. Platlets
then adhere to the degraded endothelium. These platlets are frequently
degranulated and associated with strands of polymerized fibrin. Platlet
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sticking is followed by stasis and these two events appear to be the
trademark of capillary regression.
Preliminary experimental evidence suggests that certain angiogenesis
inhibitors provoke similiar events. Little is known about why an
endothelial cell in a new capillary suddenly loses its ability to repel
platlets once a neovascular stimulus is removed; whereas, the endothelial
cells of more established vessels do not.
Once stasis occurs, endothelial cells degenerate. Macrophages move
in perivascular tissue to surround the degenerating capillaries and
ingest cell debris. Stasis and phagcytosis proceed in a retrograde
manner from the tip of the capillary. After six to ten weeks all vessels
are replaced by lipid filled macrophaaes(termed foam cells for their
appearence under light microscope) and a few fibroblasts. Only the thin
white threads of the largest primary vessels mark the location of the
original capillary plexus.
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1.3 Theories of Metastasis
Metastasis is the spreading of tumor colonies from malignant cells
that detach themselves from the primary tumor and travel through the
body, usually but not exclusively, via the vascular system, and often to
distant sites. The development of metastasis involves a complex sequence
of interdependent events best conceptualized as a stairway depicted in
figure 1 where each step must be successfully surmounted to eventually
produce a secondary implant.
Progressive
Evasion of host
defense
Extravasation
Arrest
Survival in the
circulation
Embolization
Detachment
Invasion
Climbing the Stairway to
Metastasis
Vascularization
Progressive
growth
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Figure 1: Sequential development of processes leading to metastasis.
The initial steps in this sequence were discussed in the previous
section. Starting at the invasion level the detached cells from a
primary carcinoma may first enter open lymphatics, and then thin walled
veins, or less commonly thicker walled arteries. Sarcomas tend to enter
blood vessels earlier unlike carcinomas that enter lymphatics first.
From the lymphatics the cells spread to the regional lymph nodes, where
the tumor may be arrested. If not, growth in nodes and furthur
dissemination occurs eventually reaching the circulatory system. A
tumor's growth may also block a lyphatic duct leading to a reverse
spread. In general, once the cells have invaded the vascular or
lymphatic channels they may either grow at the site of penetration or,
because of their loss of cohesiveness, be swept away as individual cells
or small embolic clumps. In this exposed situation they are vulnerable
to humoral or cell-mediated immune responses and to nonimmune defenses
such as destruction by activated macrophages or natural killer(NK) cells.
Conversely they may become coated with polymerized fibrin(Dvorak,
H.F.,1979;Chew, E.C. and Wallace, A.C., 1976) or platlet aggregates, both
of which could enhance survival of intravasular cancer cells, and
therfore the formation of metastases. The cells that survive must then
arrest in the capillary beds of distant organs either by adherence to
endothelial cells or attachment to vascular basement membrane exposed by
endothelial cell retraction(Kramer, R.H. and Nicolson, G.L.,1979). The
arrest of circulating tumor cells is not a haphazard process, rather
extravasation of cells at sites of arrest presumably involves the same
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1.4 umor Patholgy and Nomenclature
All tumors benign and malignant, have two basic components:
(1) proliferatirng neoplastic cells that constitute their parenchyma
and
(2) supportive stroma made up of connective tissue, blood vessels,
and possibly lymphatics.
Although parenchymal cells represent the "cutting edge" of neoplasms
and so determine their nature, the growth and evolution of neoplasms are
critically dependent on their stroma. An adequate stromal blood supply is
requisite and the stromal connective tissue provides the framework for the
parenchyma. In some tumors the stromal support is scant, and so the
neoplasm is soft and fleshy. Sometimes the parenchymal cells stimulate
the formation of an abundant collagenous stroma(referred to as
desmoplasia). Such tumors as, for example, some cancers of the female
breast are stony hard or scirrhous.
The nomenclature of tumors is, however, based on the parenchymal
component. The suffix "oma" denotes a benign neoplasm. Benign
mesenchymal tumors(those arising in muscle, bones, tendon, cartilage, fat,
vessels, and lymphoid and fibrous tissue) are classified histogenetically
according to parenchymal cell type.
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Malignant tumor nomenclature essentially follows the same schema used
for benign neoplasms with certain additions. Cancers arising in
mesenchymal tissue are called sarcomas because they usually have very
little connective tissue stroma and so are fleshy(Greek "sarc-" = fleshy):
e.g. rhabdomyosarcoma for a cancer arising in straited muscle. Malignant
neoplasms of epithelial cell origin, derived from any of the three germ
layers, are called carcinoma. One with a glandular growth pattern
microscopically is termed and adenocarcinoma, and one producing
recognizable squamous cells arising in any of the stratified squamous
epithelia of the body would be termed a squamous cell carcinoma. Finally,
it is common practice to specify, when possible, the organ of origin, e.g.
a renal cell adenocarcinoma for a glandular epithelial neoplasm from the
kidney.
Nearly all benign tumors grow as localized expansile masses enclosed
within a fibrous capsule. They remain localized to their site of origin
and cannot disseminate throughout the body. The capsule comprises an
enclosing fibrous membrane, in part derived from the fibrous stroma of the
surrounding normal tissue and in part elaborated by the tumor. Such
encapslation tends to contain the benign neoplasm as a discrete readily
palpable, and easily movable mass that can be surgically enucleated.
Cancers are almost never encapsulated and are characterized by
infiltrative, erosive growth that extends crablike feet into adjacent
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tissues. Slowly expanding malignant tumors may develop an apparently
enclosing fibrous membrane and may push along a broad front into adjacent
normal structures. However, histologic examination will almost always
disclose tiny pseudopods indicative of penetrating spread.
Most cancers are obviously invasive and can be expected to penetrate
the wall of the colon or the uterus, for example, or fungate through the
surface of the skin. They recognize no normal anatomic boundaries and
often permeate lymphatics, blood vessels and perineural spaces as
previously noted. Such invasiveness makes their surgical resection
exceedingly difficult and generally requires removal of a considerable
margin of apparently normal tissues about the infiltrative neoplasm; this
is referred to as radical surgery. In fact, next to the development of
metastases, invasiveness is the most reliable feature that differentiates
malignant and benign neoplasms.
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1.5 A Vascular Metastatic Pathway
In this work the existence of open-ended tumor vessels in the tumor
hypoxic region is established. It is postulated that one pathway through
which malignant cells could enter the circulation is through open-ended
tumor vessels. These open vessels are thought t be created by the
degradative action of active lysosmal enzymes diffusing outward from the
tumor necrotic region towards the endothelium of closed tumor vessels
(Weiss, 1978; Turner,1980). A polymer casting method and scanning
electron microscopy are used to investigate tumor microvasculature (Shah,
1983; Babayan,1984; Nelson, 1984) and an inverse square correlation is
established between the time to metastasis and the number of open-ended
tumor vessels. This correlation provides substantial evidence that the
open tumor vessel system provides a pathway for metastasis.
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1.6 Models for Tumor Vascular Morphology
The current view of the morphology of tumor vasculature(Peterson,
1979) is that it is located only on the periphery of the expanding tumor
and forms a closed vascular network(i.e no open-ended vessels). In the
present investigation the hypothesis is that if a tumor engulfs any
fraction of its own vasculature as it grows, then it may leave beneath its
expanding surface vasculature which may become open-ended. This open
system provides a mechanical pathway for the migration of tumor cells into
the main circulatory system where they may be subsequently sequestered in
the vascular endothelium of the target tissue. This pathway could explain
how the secondary growth at the site of the target tissue may be
initiated.
If the tumor vasculature is exclusively peripheral then expansion of
the tumor peripherally and the concurrent expansion of the necrotic region
internally would not result in open-ended vessels(Figure 2a). However if
the peripheral vessels contain radially directed branches then internal
expansion of the necrotic region could lead to vessel degradation(Figure
2b). Therefore, the first step in the establishment of open-ended tumor
vessels is to establish that radial tumor vessels exist.
In this investigation the establishment of open-ended tumor vessels
and its connected vascular network allows for the statement of the
fol' ing hypothesis:
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HYPOTHESIS
Open-ended inward directed radial capillaries in solid tumor could
provide passage to the main circulatory system for cancer cells that have
detached from the non-necrotic region of the tumor, thus providing a
physical pathway mechanism for metastasis.
PERIPERAL TeOR
VASCULATURE
NECRO
BoREF
VASCUATUE
FiGmE 2B T: TANiENTIAL
fR: RADIAL
Figure 2a: Conventional model of tumor vessel growth.
2b: Proposed model of tumor vessel growth.
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1.7 Thrombin As A Potential Chemotherapeutic Agent:
Thrombin, a direct acting coagulant, is a protein substance produced
in mammals through a conversion reaction in which pro-thrombin is
activated by tissue thromboplastin in the presence of calcium chloride.
As a tumor therapy agent, thrombin may be useful in reducing tumor
perfusion and blocking metastasis. More specifically, an injection of
thrombin into the tumor necrotic region allows the coagulant to diffuse
through the tumor mass and permeate the tumor vasculature(via the open-
ended radial tumor vessels) to form thrombi. Thrombus formation serves
two anti-tumor functions(D'Amico, 1986). First, thrombus formation
restricts blood flow and concomitantly reduces tumor perfusion giving
rise to tumor hypoxia, hypolycemia, and deficiencies in other blood borne
compounds(e.g. vitamins, amino-acids, minerals). These deficiencies
promote tumor necrosis. Second, thrombosis of the tumor vasculature
reduces the possibilty of metastasis by sealing off the tumor vessel
system from the rest of the organism's circulatory system.
Because the metastatic colonies are harder to detect than the
original tumor and, moreover; are often impossible to treat successfully,
metastasis can be considered clinically as the conclusive event in the
natural history of cancer(Nicolson, 1979). Therefore, a therapy(such as
the one described here) that has both anti-tumor and anti-metastatic
effects could be effective in the long term control and eventual
elimination of malignancies in patients.
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2. EXPERIMENTAL METHODS
2.1 Tumor Vascular Studies:
In the first part of this work, tumor vascular studies are performed
to enable the understanding of the three-dimensional morphology of tumor
neovasculature. The methods involve the creation of a plastic cast
replicas of the tumor vasculature which are examined under a scanning
electron microscope.
2.1a Animal Surgery and Tumor Implantation
The spontaneously arising renal adenocarcinoma of the clear cell
type is implanted in the renal capsule of the Wistar-Lewis rat's left
kidney while the right is used as a control. The Wistar-Lewis rat is
used as the test subject, because there is no immunological rejection
when the adenocarcinoma tumor is implanted under the renal capsule(White,
1980). The tumor tissue was obtained from Dr. Richard Babayan at Boston
City Hospital, Boston, Massachusetts.
Renal adenocarcinoma is found in this study and others(Babayan,
Nelson; 1984) to have its primary metastatic site at the lung
approximately eight weeks post-implantation in the renal capsule. Most
rats die at about ten weeks post-implantation due to inadequate alveolar
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surface area for blood gas exchange resulting from the presence of tumor
on the pulmonary tissue. A small percentage(less than 2%) of the rats in
this study lived long enough to sustain a secondary hepatic metastasis at
12 weeks post-implantation.
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2.1b Polymer Casting of Tumors
In one week intervals from three weeks up to a maximum of six weeks
post tumor implantation, a surgical procedure was performed on 15 rats(in
each age group) to create a "closed vascular system" involving both of
the rat's kidneys and the lower abdominal aorta and inferior vena
cava(figure 3).
ial aorta
:idney
renal adenocarcinoma
Figure 3: Closed vascular system used for the preparation of kidney-tumor
system.
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lower
abdomi
vena
cava
right
kidney
This system was catheterized through the lower abdominal aorta. The
aorta serves as the inlet while the vena cava serves as the outlet for
perfusion. We perfused with 50 ml of 0.85% heparnized saline n order
to drain the blood from the vascular system and prevent thrombus
formation. Then, 50 ml of 2.5% gluteraldehyde(ph=7.4, buffered with
NaH2PO4oH20 and NaH2PO4.7H20) is adminstered as a fixative. Perfusion
with the fixative ensures that the vasculature will not collapse or
rupture during polymer injection. Finally, the system is injected with a
low viscosity methyl methacrylate polymer called Mercox(Ladd Research
Industries, Inc., Burlington, VT). The polymer hardens within 15
minutes; the kidneys are surgically removed and digested in a preparation
of 5.6 N potassium hydroxide(20% by weight) at room temperature until the
biological tissue completely dissolves, leaving a plastic replica of the
kidney-tumor mlcrovasculature.
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2.1c Scanning Electron Microscopy
The small((< 2 cm diameter) plastic casts are processed for SEM in the
standard fashion of dehydration in graded ethanol, drying in a carbon
dioxide critical point dryer, and mounting on aluminum stubs for gold
sputter coating. The larger casts were air dyred before mounting. All
specimens(15 from each age group) were studied under the scanning
electron microscope(ISI DS-130) which is operated at 20 kV potential in
the secondary electron model. During data collection several views of
the specimens were obtained by using the tilt mechanism on the SEM.
Viewing the specimen in several different planes allowed for a three
dimensional visualization of the tumor vascular morphology.
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2.2 Thrombin Therapy
Animal surgery, polymer corrosion casting method, scanning electron
microscopy(SEM), and histology are used to investigate the effects of
thrombin therapy on tumor microvasculature. Figure 4 is a flow chart of
the various procedures performed on 104 Wistar-Lewis rats and 16 Wag-Rij
rats used in this study.
IME OF EXPIRATION(T)
PREPARATION
MOLOGY PREPARATIO (N)
IME OF EXPIRATION (T)
PREPARTION
roLOGY PEPARATION0(i)
X 104
IOR
IMPAffA
T = 0 WEKS
X' Lrs WI J J: RIAETER MEASUREENT AT
Y #OF RATS WITH A OSAR Tl: b OR / EEKS POST IPLANTATION
Figure 4: Flowchart of experimental methods.
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The spontaneously arising renal adenocarcinoma and rhabdomyosarcoma
are implanted under the left renal capsule of the Wistar-Lewis and Wag-
Rig rats respectively while the right kidney in each is used as a
control. A 1 mm3 mass of adenocarcinoma tumor tissue s implanted
beneath the Wistar-Lewis rat's left renal capsule where there appears to
be no immunological rejection of the tumor mass(White, 1980). Similarly,
the rhabdomyosarcoma tumor tissue was implanted under the Wag-RIj rat's
renal capsule(Barendsen,Broerse; 1969,1970).
At six weeks post implantation the rat's left kidney-tumor complex is
exposed and examined. The tumor diameter is measured(measurement is
obtained by taking the square root of the product of the largest and
smallest diameters) and then one half of these animals (52 Wistar-Lewis
rats and 8 Wag-Rij rats) are returned to their cages untreated to serve
as controls. The remaining half of the animals(52 Wistar-Lewis rats and 8
Wag-RiJ rats) are given a single injection of thrombin into the center
of the tumor necrotic region after which they are returned to their
cages.
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2.2a Thrombin Dose Calculation
The thrombin dose administered is a function of tumor radius and has
been calculated(Appendix D). It is assumed that the injected dose of
thrombin diffuses isotropically through tumor tissue and can be modeled
as an instantaneous point source. Under these conditions the
concentration of thrombin as a function of radius(r) and time(t) is given
by equation 1.
C(r,t) = (U/8(rDt)l.5)e(-r2/4Dt) (1)
where:
U: the number of units of thrombin delivered to
the tumor necrotic region
D: 1.8 E-5 cm2/sec [Thrombin diffusion coefficient]
Figure 5 shows a graph of the solution to equation (1). The
therapeutic thrombin dose in this study is 2 units of thrombin(stock
solution is 5000 U/ml) to clot 1 ml. of animal's blood in 15 seconds.
From figure 5 one can note that at a time(t) equal to tmax the
concentration of thrombin is at a maximum at the location, r = (6Dtmax)'5
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from the point of thrombin injection. The time, tmax s of interest
because by evaluating equation 1 at t = tmax for a given tumor radius,
rtumor and using C-therapeutic = 2 units thrombin/ml blood for C(r,tmax),
one can solve for the number of thrombin units, U needed such that at time
t - tmax the thrombin concentration C(r=rtumor,tmax) would have reached
therapeutic levels throughout the entire tumor. The calculation of U is
contained in Appendix D.
C(r, t
C
o
r
rl r 2 <r 3
0
Figure 5: Concentration profile in time for varying tumor radii, note
tmax is shown for r=r2.
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To calculate tmax one looks for the critical point in the C(r,t)
function in the time domain as follows:
From dC(r,t)/dt /= 0 (2)
ttmax
one finds:
tmax = r2 /6D (3)
Table 1 gives the tmax and tumor radius, rtumor, with the corresponding
number of units of thrombin, U, required for therapy as determined from
equation 1.
rtumor(cm) # Units of thrombil tmax(hours)
0.5 50 0.64
1.0 400 2.60
1.5 1,348 5.80
2.0 3,194 10.3
2.5 6,239 16.1
3.0 10,781 23.2
Table 1: Summary of the proper thrombin dosage and time, tmax to achieve
a maximum thrombin concentration at the tumor boundaries for tumors of
varying radii.
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2.2b Specialized Vascular Casting
After the rat kidney-tumor system is njected with the appropriate
thrombin dose, half of the treated animals(26 Wistar-Lewis, 4 Wag-Rij)
are maintained until death and their expiration date and cause of death
are noted while the remaining animals(26 Wistar-Lewis, 4 Wag-Rij) are
held one week and then undergo a vascular casting procedure and a tumor
diameter measurement. As can be seen from the tmax times listed in Table
1, one week is ample time for the drug to have reached therapeutic levels
in all tumor regions for the tumor specimens used n this study(i.e.
rtumor < 6 cm).
A specialized vascular casting procedure was performed on half of
the thrombin treated animals (26 Wstar-Lewis, 4 Wag-Rij) nvolves
surgical exposure of the rat's left kidney-tumor complex followed by a
polymer injection of methyl methacrylate, Mercox (Ladd Research
Industries, Inc., Burlington, Vt.) into the center of the tumor necrotic
region. After injection under hand pressure(approx. 50 torr) the polymer
is allowed to harden for thirty minutes. Approximately half of the
casted specimens(13 Wistar-Lewis,3 Wag-RiJ) are sectioned into 5 mm
slices and stored in Sierra's fixative(Appendix A) in preparation for
histological slide preparation(Appendix A).
The remaining casted specimens are prepared for SEM(13 Wistar-Lewis,
1 Wag-Rij). Preparation for SEM involves digestion of the kidney-tumor
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casts in 20% by weight solution of potassium hydroxide(5.6 N), followed
by dehyradation in graded ethanol, drying in a carbon-dioxide critical
point dryer, and mounting on aluminium stubs prior to gold sputter
coating. The specimens are studied under the SEM (SI DS-130) which is
operated at 20kV potential in the secondary electron mode.
For the untreated(control) animals(52 Wistar-Lewis, 8 Wag-RiJ) the
tumor diameters are measured at six weeks post implantation. Half of
these animals(26 Wistar-Lewis, 4 Wag-Rij) are caged and are monitored as
to the time and cause of death. The remaining animals(26 Wistar-Lewis, 4
Wag-RiJ) undergo the specialized vascular casting procedure at seven week
post implantation previously described. Finally, approximately half of
the casted specimens (13 Wistar-Lewis, 1 Wag-Rij) are prepared for SEM
examination; whereas the rest of the casted control specimens(13 Wistar-
Lewis, 3 Wag-RiJ) are processed for histological sectioning(Appendix A)
and light microscope slide production(Appendix A).
The cause of death in all cases of both control and treated rats is
pulmonary metastasis to both lungs leading to insufficient alveolar
surface area for blood gas exchange(White, 1980). In all cases examined
the fatal metastasis occured at two weeks + one day prior to animal
expiration and, as a result, the time to metastasis is given as the time
to animal expiration minus two weeks(+ one day).
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2.2c Histological Preparation
The histological slide preparation(Appendix A) involves specimen
dehydration in ethanol and chloroform, followed by infiltration and
embedment n paraffin at 600C. The embedded specimens are cut nto ten
micron thick slices, mounted on glass slides, and stained with
hematoxylin and eosin. These slides are examined under a Zeiss 47 79 01
9901 light photomicroscope III.
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3. RESULTS
The results of both the tumor vascular studies and thrombin therapy
trials are presented. Open-ended radial vessels are established with at
least 95% certainity and the efficacy of thrombin as an anti-metastatic
agent is validated.
3.1 Testing of a New Model for Tumor Vascular Morphology
To show with adequate statistical certainty that radial tumor
vessels exist, a student t-test is performed on the data collected from
the kidney-tumor polymer cast specimens. Any capillary that points
radially inward gets counted provided its angle with the tangent plane at
the tumor surface is greater than 30 degrees(Figure 2b, Figure 7). This
criterion was imposed to ensure that the vasculature was in fact pointing
towards the tumor center and not lying along the tumor surface(i.e.
peripheral).
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3.1a Calculation of the Sample Area
In performing the student t-test a sample area size must be
determined. A square area of 500 um x 500 um is adopted to ensure that
within any square area of evaluation there could be at least one data
point. The determination of the dimensions of the sample area was
performed as follows: The average intercapillary distance for tumor
systems examined in this study is 190 um(Peterson, 1979) . Using the
intercapillary distance(ICD) one can construct a circle of capillaries
around a central capillary such that all capillaries are at a distance of
190 um from one another(Figure 6a). If one inscribes a square within the
circle which encloses only one capillary, this square area would
represent the choice for which a value of unity would be obtained as the
data point. Therefore by calculating the dimension of this inscribed
square one can find the smallest allowable dimension of the sample area
such that at least a value of unity could be obtained on any given
counting trial. The length of the side(L) is given by equation 4 in
terms of the ICD.
L = (2) 5 ICD (4)
Evaluating equation 4 for the tabulated ICD gives a dimension L of 266
um. The method described represents the closest possible packing of
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capillaries. In order to be certain that the largest possible sample size
has been choosen to include one capillary, evaluation of the capillary
packing shown in figure 6b should be analyzed since it represents the
least dense close packing of capillaries. In this case the dimension of
the sample area side is 2ICD or 380 um. In this study the conservative
value of 500 um is choosen because the ICD reported is an average and may
vary as much as + 20 um depending upon the tumor and its size.
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Figure 6a: Illustration of the calculation to determine the sample area
dimensions(closest packing).
6b: Illustration of the calculation to determine sample area
dimensions(least dense packing).
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3.1b The Counting Experiment: Methods and Results
Each of forty different tumor specimens(10O from each age group) are
measured as follows:
(1) For a given tumor age(i.e. 3, 4, 5, and 6 weeks) 500 um x 500 um
squares of tumor surface vasculature are examined under
SEM(magnification = 200X, approximately).
(2) For the fixed 2.5 E+5 um2 area(box shown in figure 2b, figure 7) the
number of radial tumor vessels satisfying the criterion stated above
are counted and this number serves as a data point. One hundred
sample areas are chosen randomly for each specimen to avoid biasing
the data.
(3) For a given tumor specimen as many as three different angles of view
are chosen for each observation in order to establish the angular
arrangement of tumor vascular morphology(See figure 7). These three
views were obtained by tilting the SEM specimen stage at angles
varying between + 15 degrees.
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/Three dimensional representation of the method of data
collection.
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Figure 7:
\1
(4) The null hypothesis being tested is that there are no radial tumor
vessels within the square surface area of 2.5 E+5 um2 existing
inside the renal adenocarcinoma ( = 0.0 in equation 5). With a
standard t-metric test, the acceptance region for the null
hypothesis is calculated from equation 5.
(5) Then the experimentally determined mean number of radial tumor
vessels(average of 100 data points) is compared with the acceptance
region for the null hypothesis.
- t.s(d)s/(n-1). 5 < x < + tl-.5a(d)-s/(n-1) -5 (5)
where:
x: experimental average number of radial tumor vessels per sample
area(100 data points, xi were averaged)
/A: true mean number of radial tumor vessls per sample area
n: number of trials
s: experimental standard deviation
d = n-l: number of degrees of freedom
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(from the definition of t-distrlbutlon)
t(d): t-value from t-distribution tables(Duncan,1977)
a: confidence level(e.g. a = 0.05 = 95% confidence interval)
The results of this investigation lead to the rejection of the null
hypothesis and acceptance of the alternative hypothesis that inward radial
tumor vessels exist with a certainty of at least 95%(a = 0.05). Values
for the maximum and minimum true means are calculated using the collected
data, x, according to equations (6) and (7). The maximum and minimum
mean values set the limits on the possible variation n the true mean
number of radial tumor vessels for the number of trials performed(n=100)
and at the confidence levels stated(95%, 99%). The results of the data
analysis are summarized in Table 2.
Pmin x - tl-.5a(d)-s/(n-1).5 (6)
Imax = x + tl_.5(d)s/(n-1)5 (7)
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Tumor Age Acceptance x** /min /max
(weeks) Interval for
Null Hypothesis
3 0.0-0.24 3.7 3.46 3.94
4 0.0-0.28 4.4 4.12 4.68
5 0.0-0.40 5.0 4.60 5.40
6 0.0-0.50 6.2 5.70 6.70 95% C.I.
3 0.0-0.32 3.7 3.38 4.02
4 0.0-0.47 4.4 4.03 4.77
5 0.0-0.53 5.0 4.47 5.53
6 0.0-0.66 6.2 5.54 6.86 99% C.I.
** 100 data points were averaged to obtain the numbers in this column
Table 2: Summary of the minimum and maximum true and experimental mean
values for all tumor casts examined(the numbers above reflect
data obtained from 10 kidney-tumor casts for each tumor age
group).
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3.2 Thrombin Therapy: A matched pair cohort study
Thrombin, a direct acting coagulant is administered to the center of
the tumor necrotic region to examine whether the diffusion of the drug
into the tumor vascular network will result in circulatory blockage from
vascular thrombosis. Once the vessels are sealed the vascular metastatic
process is impeded and tumor perfusion is sharply reduced(i.e. ischemia)
leading to increased tumor necrosis.
Table 3 summarizes the tumor diameters at six weeks post tumor
implantation(TD 6) and the time to death post tumor implantation(t) as
well as the number of open-ended tumor vessels(N) in a fixed 2.5 E=5 um2
square surface area for both tumor systems and both the thrombin treated
and control cohorts.
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CONTROL TREATED
N t(days) Tumor Dia. (cm.) N t(days)
(t 6 weeks)
Renal Adenocarcinoma
9.5+1.0 72+0.5 4.5+.05 4.8+.47 131+0.5
8.8+.85 73+0.5 4.0+.05 4.1+.39 133+0.5
8.0+.80 75+0.5 3.5+.05 3.4+.35 139+0.5
7.8+.78 76+0.5 3.2+.05 3.3+.30 140+0.5
7.7+.75 78+0.5 2.6+.05 3.1+.28 142+0.5
7.6+.74 78+0.5 2.1+.05 2.9+.27 145+0.5
7.5+.71 80+0.5 1.5+.05 2.8+.25 147+0.5
7.5+.72 81+0.5 1.0+.05 2.7+.26 149+0.5
7.3+.71 80+0.5 .75+.05 2.6+.24 151+0.5
7.2+.70 81+0.5 .50+.05 2.5+.24 154+0.5
Rhabdomyosarcoma
8.5+.82 69+0.5 2.5+.05 2.4+.25 89+0.5
7.0+.71 72+0.5 1.6+.05 2.2+.21 91+0.5
6.8+.70 74+0.5 1.2+.05 2.1+.20 94+0.5
Table 3: Summary of the number of open-ended tumor vessels(N), the time
to animal expiration post tumor implantation(t), and the tumor
diameter pre-thrombin therapy(t=6 weeks) for both tumor
systems including the control and treated cohorts.
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In the treated cases, therapy is adminstered at six weeks post
implantation and polymer casts and histological slides are made at seven
weeks post implantation. As mentioned previously, one week is ample time
for the thrombin concentration to reach therapeutic levels in the entire
tumor region; therfore, the measurement of N after therapy at seven weeks
post implantation using histology will reflect the effects of the drug on
the status of the open-ended tumor vessels. N is d&termined by counting
the number of polymer(blue) filled vessels per 2.5 E+5 um2 square surface
area on the histology slides.
The square area of 500 um x 500 um is selected to ensure that within
any area of evaluation there will be at least one data point. The
determination of the dimensions of the sample area was previously
explained. Figure 8 is a histological cross section of renal
adenocarcinoma taken after both thrombin therapy and polymer injection.
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Medial cross section of renal adenocarcinoma after
therapy(t= 6 weeks) and casting(t= 7 weeks). Note the
appearence of both clotted tumor blood vessels(red) and
polymer filled(blue) blood vessels within the 2.5 E+5 um2
sample area.
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Figure 8:
Figure 8: Medial cross section of renal adenocarcinoma after
therapy(t= 6 weeks) and casting(t= 7 weeks). Note the
appearence of both clotted tumor blood vessels(red) and
polymer filled(blue) blood vessels within the 2.5 E+5 um2
sample area.
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diai meter renal adenocarcinoima taken after treatlent. Note,
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extending from the cenrtral polymer mass(necrotic region).
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Note the presence of both polymer filled(blue) and thrombosed(red)
blood vessels. Only those vessels that remain open after therapy will
provide access for polymer infusion after ts administration to the
center of the tumor necrotic region. Also, llustrated in figure 2b(also
figure 7) is the square sampling area used to collect data(N) on the
number of open-ended tumor vessels.
Figure 9: A scanning electron micrograph of a polymer casted 3.5 cm
diameter renal adenocarcinoma taken after treatment. Note,
the finger like projections(open-ended blood vessels)
extending from the central polymer mass(necrotic region).
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Figure 9 is one representative electron micrograph showing a polymer
casted specimen. Note the central region of polymer that fills the
necrotic region of the tumor, and the finger like protrusions extending
from the central polymer mass. These protrusions are pathways which
provided an outlet through which the polymer could flow. A careful
investigation of the surface morphology of the casts(i.e examination for
endothelial cells) shows that these cylindrical structures are blood
vessels. Therefore, in order for the polymer to enter these vessels they
would have to be open-ended.
The results in table 3 for N and t are evaluated using a students t-
metric (for a matched pair study) to test the following null hypotheses:
1Ho: There is no difference in the time,'t' to animal death(lung
metastasis) between the control and treated cohorts.
2Ho: There is no difference in the number of open-ended tumor
vessels, 'N' in the control and treated cohorts.
The statistical test is performed on each pair of control-treated
data pairs that were matched for tumor diameter at t=6 weeks(pre-
treatment). The matching ensured that the tumor geometry at the cellular
and vascular levels were comparable before therapy. The student t-metric
for a matched pair study is used in the evaluation and is given by:
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t x/(s/(n). 5 ) (8)
where:
x: mean difference in the variable(N,t) before(control) and
after treatment.
s: standard deviation in the difference results
n: number of trials
The results of the test show that with at least 99% certainity there
is a significant difference in the treated and control groups values for
N and t. Specifically, the treated group had a larger time to animal
death(lung metastasis) and a lower number of open-ended tumor vessels.
The 99% confidence intervals for the difference in N and t between the
control and treated cohorts are as follows:
Adenocarc noma:
t: [61.16, 70.24] with mean = 65.7 days
N: [4.59, 4.75] with mean = 4.61
Rhabdomyosarcoma:
t: [16.37, 22.97] with mean = 19.67 days
N: [0.78, 9.62] with mean = 5.2
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4. DISCUSSION OF RESULTS
In this section the morphological details of tumor vasculature are
examined. A vascular metastatic pathway is established and the efficacy
of thrombin as a new cancer chemotherapeutic agent is investigated.
4.1 Tumor Versus Renal Vascular Morphology
It is instructive to examine some relevant features of normal kidney
vasculature and compare these features with those of tumor vasculature.
Figure 10 shows normal kidney vasculature.
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Figure 10: Micrograph of normal kidney vasculature.
Note that this vasculature is organized in parallel sets of
capillaries that gather at masses called glomeruli. The glomerulus is a
tuft of capillary loops projecting into the expanded end (Bowman's
capsule) of each of the uriniferous tubules. Another feature of the
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Figure 10: Micrograph of normal kidney vasculature.
Note that this vasculature is organized in parallel sets of
capillaries that gather at masses called glomeruli. The glomerulus s a
tuft of capillary loops projecting into the expanded end (Bowman's
capsule) of each of the uriniferous tubules. Another feature of the
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comparison is that the diameter of the normal kidney vasculature is
similiar to that of tumor microvasculature, being not less than 10 um. In
contrast, the tumor microvasculature in Figures 11, 12a, 12b, and 13 show
noteworthy features that differ from those of the normal kidney vessels.
These dissimilarities include the following:
(1) A major vessel can have multiple branches(Figure 11).
Figure 11: Example of sprouting found in tumor microvasculature. The
interface between the kidney and tumor is depicted. Notice
the inward pointing tumor vasculature and sprouting vascular
buds.
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(2) In conjunction with statement (1), there are mitotic endothelial
cells located on small buds sprouting off the main vessel. Mitotic
endothelial cell imprints are distinct from resting endothelial cell
imprints in that they show a smooth but indented surface due to a
nuclear bulge(figure 12a, 12b). The presence of these mitotic cells
suggests that a growing vessel stems from the location of the
mitotic capillary endothelial cells. As mentioned in the
introduction, this growth may be stimulated by and directed towards
tumor cell secreted TAF(Folkman. 1Q97).
Figure 12a: Micrograph of endothelial cell nuclei located on small buds
sprouting off the main vessel.
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(2) In conjunction with statement (1), there are mitotic endothelial
cells located on small buds sprouting off the main vessel. Mitotic
endothelial cell imprints are distinct from resting endothelial cell
imprints in that they show a smooth but indented surface due to a
nuclear bulge(figure 12a, 12b). The presence of these mitotic cells
suggests that a growing vessel stems from the location of the
mitotic capillary endothelial cells. As mentioned in the
introduction, this growth may be stimulated by and directed towards
tumor cell secreted TAF(Folkman. 1975).
Figure 12a: Micrograph of endothelial cell nuclei located on small buds
sprouting off the main vessel.
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Figure 12b: Higher magnification view of endothelial cell
on small buds sprouting off the main vessel.
nuclei located
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INTENTIONAL DUPLICATE EXPOSURE
(3) Mitotic endothelial cells are also located on the periphery of some
tumor vessels, ndicating direct growth(Figure 13). The indented
region on the outer perimeter of the tumor blood vessel is exemplary
of a mitotic endothelial cell.
From Figure 11 and other work(Shah, 1983; Babayan, 1984; Nelson,
1984) it is apparent that the tumor vasculature near the kidney tumor
interface is composed of kidney vasculature which is initially normal and
then becomes altered due to the presence of the growing tumor. Figure 14
shows the kidney-tumor interface from a 6 week tumor cast. In this
figure one observes the presence of modified kidney vasculature(diameter
approximately 10-40 um) and the proliferation of new tumor
capillaries(diameter approximately 10 um) both at the kidney-tumor
interface.
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Figure 13: Radial growth is suggested by the endothelial
cell(indentation in cast) located on the periphery of the
tumor capillary.
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Figure 13: Radial growth is suggested by the endothelial
cell(indentation in cast) located on the periphery of the
tumor capillary.
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Figure 14: Micrograph of modified kidney vasculature(diameter approx.
10-40 um) and new tumor capillaries(diameter approx. 10 um)
at the kidney-tumor interface.
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Fure 14: Micrograph of modified kidney vasculature(diameter approx.
10-40 um) and new tumor capillaries(diameter approx. 10 um)
at the kidney-tumor interface.
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4.2 A Vascular Metastatic Pathway
Apparently two classes of radial tumor vessels exist. The first
class depicted in figures 11, 12a, 12b, and 13 seems to be comprised of
vessels growing radially inward and which are closed-ended. The second
class depicted in figures 15 and 16 appears to be comprised of vessels
that are dying, open-ended and are proximally located to the tumor
necrotic region.
Figure 15: An open-ended dying tumor capillary(diameter approx. 10um)
located adjacent to the tumor necrotic zone(dark portion of
micrograph in lower right).
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4.2 A Vascular Metastatic Pathway
Apparently two classes of radial tumor vessels exist. The first
class depicted in figures 11, 12a, 12b, and 13 seems to be comprised of
vessels growing radially inward and which are closed-ended. The second
class depicted in figures 15 and 16 appears to be comprised of vessels
that are dying, open-ended and are proximally located to the tumor
necrotic region.
Figure 15: An open-ended dying tumor capillary(diameter approx. 10um)
located adjacent to the tumor necrotic zone(dark portion of
micrograph in lower right).
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Figure 16: An illustration of a branched tumor vessel located partially
within the necrotic region which is in the process of
collapsing and becoming open-ended.
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Figure 16: An illustration of a branched tumor vessel located partially
within the necrotic region which is in the process of
collapsing and becoming open-ended.
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A plausible explanation for the existence of two types of tumor
vessels s illustrated in figure 2b. Note that the closed-ended tumor
vessels are growing radially inward and are located distally from the
outer surface of the tumor necrotic region. This class of vessels stems
from larger diameter peripheral tumor vessels located in the oxygenated
circumferential region of the tumor. The open-ended tumor vessels are
located proximally to the tumor necrotic region. It is proposed that as
the necrotic region enlarges, those engulfed vessels or pieces of vessels
within the growing necrotic volume will decompose, resulting in
apparently open-ended(i.e. terminated or dead end) tumor vasculature in
the 'non-necrotic' region of the tumor mass. The open-ended tumor
vessel system is nterconnected to the larger diameter tumor vessels
located in the well oxygenated periphery of the tumor. These larger
vessels are connected to the renal vasculature which leads to the
Inferior vena cava via the renal vein. In summary, the open-ended
vessels can serve as a pathway leading to the main circulatory system
from the primary tumor mass as previously stated in the introduction as
the hypothesis.
The cancer cells tt have access to the open-ended vessel network
are likely to be in the hypoxic region of the tumor,(i.e. the region
surrounding the anoxic tumor necrotic region) and as a result are
probably in a resting phase. The resting phase exists because the region
directly adjacent to the tumor necrotic region is of low oxygen tension,
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hypoglycemic, and lacking in other needed cell nutrients due to
inadequate perfusion to this tumor region(Weiss, 1978). If these cells
are exposed to adequate oxygen tension and other needed nutrients they
can eventually begin to proliferate(Kallman, 1972). Therefore, if one or
more of these resting cells entered the open tumor vessel pathway, it can
travel to adequately perfused regions of the tumor, renal vasculature, or
even the main circulatory system. In these regions of sufficient
nutrient supply the resting cells could begin to proliferate and
potentially create a microtumor which could travel through the vascular
system and subsequently be trapped in the vascular endothelium at the
secondary metastatic site.
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4.3 Evidence for the Proposed Metastatic Pathway
The behavior of both N, the number of open-ended tumor vessels and t,
the time to animal expiration post tumor implantation observed after
thrombin therapy suggests that tumor vasculature is involved in the
metastatic process. Table 4 lists the percentage change in N and t
after therapy for each matched data pair. The percentage change is
given by equation 9.
% change = [(X'-Xo)/Xo] x 100 (9)
where:
Xo: Value of variable before treatment(Control cohort)
X': Value of variable after treatment (Treated cohort)
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Renal Adenocarcinoma
Tumor Diameter(cm) N'-No t'-to (N'-No)/(No) (t'-to)/(to)
(t 6 weeks) (days) x 100 x 100
4.5 -4.7 59.0 -49.5% 81.9%
4.0 -4.7 60.0 .-53.4% 82.2%
3.5 -4.6 64.0 -57.5% 85.3%
3.2 -4.5 64.0 -57.6% 84.2%
2.6 -4.6.. 64.0 -59.7% 82.1%
2.1 -4.7 67.0 -61.8% 85.9%
1.5 -4.7 67.0 -62.7% 83.8%
1.0 -4.8 68.0 -64.0% 84.0%
0.75 -4.7 71.0 -64.4% 88.8%
0.50 -4.7 73.0 -65.3% 90.1%
Rhabdomyosarcoma
2.5 -6.1 20.0 -71.8% 29.0%
1.6 -4.8 19.0 -68.6% 26.4%
1.2 -4.7 20.0 -69.1% 27.0%
Table 4: Summary of the Difference and the Difference percent for the
time to animal expiration and the number of open-ended tumor
vessels between control and treated pairs matched for tumor
diameter at t = 6 weeks post implantation.
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Thus the significant decrease in N and the pronounced increase in t
after thrombin therapy suggests that the tumor vessel network is involved
in the vascular metastatic pathway. Furthermore, the data suggests that
this pathway can be blocked via vascular thrombosis using a direct acting
coagulant such as thrombin.
To establish a functional relationship between the morphology of the
tumor vessel network and the tme to vascular metastasis a formula is
derived relating the number of open-ended tumor vessels to the time to
metastasis using Poisson statistics and first order kinetics. The
formula is then tested with the data obtained in this study(plotted in
Figures 17 a,b;18 a,b) with a non linear regression analysis(Bevington,
1969).
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Graph of N versus t for Renal Adenocarcinoma(Control).
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Figure 18a: Graph of N versus t for Rhabdomyosarcoma(Control).
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Because the number of open-ended vessels(N) per unit radius(r)
decreases linearly as the local thrombin concentration, C(r,t) increases.
dN(r,t)/dr = -kC(r,t) (10)
where:
k: rate constant(in cm2)
C(r,t): concentration profile given in equation 1.
Now integrate both sides of equation (10) with respect to r over all
possible tumor diameters leaving only the t dependence of N given by:
r= r=
N(t) = dN(r,t)/dr.dr = -kfC(r,t)dr
r=O r=O
Integrating leads to:
N(t) = 15kU/16rDt
(11)
(12)
where:
D: thrombin diffusion coefficient in blood(cm2/sec)
U: the number of units of thrombin administered
t: time post thrombin therapy
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One can relate the uncertainity in the measurement of N to the
uncertainity n the measurement of t as follows:
(aN)2 = (dN(r,t)/dt) 2 (at) 2 (13)
where:
ON : standard deviation n N
ut : standard deviation in t
Differentiate equation (12) and substitute into equation (13) to
obtain:
(aN) 2 = (t) 2 [5/256(kU/rD)2]t-2 (14)
Because the sampling size for N(100 samples per data point) is large
and any given value of N s small, Poisson sampling statistics is valid
for the measurement of N and therefore:
UN = (N). 5 (15)
Finally, equating equations (14) and (15) gives the predicted
inverse square relationship between N and t as follows:
N = (at)2.[5/256(kU/rD) 2]t-2
Since, At = t-2 weeks
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where At: time to metastasis
We have the final result that:
N a 1/(At) 2 (16)
The relationship in equation (16) is tested using regression
analysis and the correlation coefficients for both tumor systems and
groups(treated, control) are listed in Table 5.
Tumor Type Mode r(correlation coefficient)
Adenocarcinoma Control 0.950
Rhabdomyosarcoma Control 0.970
Adenocarcinoma Treated 0.999
Rhabdomyosarcoma Treated 0.970
Table 5: Listing of the correlation coefficients obtained from non-
-linear regression analysis of N proportional to (t)- 2 for both
tumor systems and control and treated cohorts.
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The results indicate that a signlficant(>95% confidence)
correlation of the type expressed n equation (16) exists. Therefore,
the theoretical relationship between N and t is supported by our
experimental results. Furthermore, an inverse square relationship
between N and t ndicates that by DECREASING N(e.g. via vascular
thrombosis) the VASCULAR METASTATIC PATHWAY s INHIBITED resulting in a
substantial TIME DELAY in the occurrence of METASTASIS.
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4.4 Cellular Detachment and Vascular Metastasis
An important question to be addressed concerns cellular detachment
within the tumor. The resting stage cells located in the tumor hypoxic
region and directly exposed to the open-ended vasculature must somehow
detach from their location before entering the open-ended vessels. The
mechanism for this detachment is believed to be due to the action of
active lysosmal enzymes present in the tumor necrotic region(Weiss, 1978;
Turner, 1980). These enzymes can promote necrotic nfiltration by lysing
neighboring cells and thereby increasing the spread of the cellular
lysosomal contents, and they can degrade the connective tissue matrix
that secures the hypoxic cells, thus permitting cells to move freely and
enter the nearby open-ended tumor vessels. Two forces are present which
can act to allow movement of the detached cells into the open-ended
vessels, namely, reaction force and Bernoulli force.
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4.4a A Reaction Force
The first force is a reaction force which originates at the center of
mass of the tumor and is directed outward toward the tumor periphery
(Figure 19).
This force develops in response to the force applied by the elastic
membrane (i.e. renal capsule) which is acting normal to the kidney
surface and inward. The outward tumor growth will be limited by the
elasticity and maximum growth rate of the renal capsule and, as a result,
eventual invasion of the tumor mass into the kidney cortex will occur.
f mass
inward elastic force supplied
by renal capsule
tward reaction force
1l capsule
Figure 19: Illustration of the generation of the outward reaction force
acting in opposition to the applied inward elastic membrane
force.
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4.4b Bernoulli Pressure Gradient
The Bernoulli pressure gradientcan generate a force as follows:
For a laminar stream of blood flow through a peripheral tumor vessel
one can define a fluid pressure, P1, velocity V1, and height h1 on a
streamline such that:
P1 + .5p1(V1)2 + mghl = Constant (17)
Similarly for an open-ended tumor vessel branching from one such
peripheral vessel(Figure 20) one can define P2, V2, and h2 on a g,^
streamline as in equation 17 so that:
P2 + .5p2(V2)2 + mgh2 = Constant (18)
Note that:
hl=h2, V1=O cm/sec, P1= P2= Pblood=1.0 0 3 gm/cm3, V2=11 cm/sec
After equating equations 17 and 18 and using the above values for the
parameters one finds that:
AP = P2-P1 = .5p2(V2)2 " 100 torr(radially outward). (19)
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AP P2-P1 = .5p2(V2)2 100 torr.
Therefore, a driving pressure of 100 torr as well as a reaction force
due to the tumors encapsulation n an elastic membrane both act on the
loosely attached tumor hypoxic cells to direct their movement towards and
into the open-ended tumor vessel network. Once in the tumor vasculature,
the cancer cells can travel via the blood stream to the main circulatory
system thus creating the possibility of metastasis.
tumor vessel
P2 V2 h2
reference pc
1 1 ".1
reference point 1
blood flow streamline
zone
Figure 20: Illustration of the Bernoulli pressure gradient and resulting
outward force generated from the blood flow velocity
differences in class 1 and class 2 tumor blood vessels.
(19)
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4.5 Thrombin Therapy's Efficacy and Clinical Usefullness
In addition to decreased tumor perfusion induced by vascular
thrombosis increased ischemia results in tumor cell anoxia and necrosis.
The necrosis then spreads through the action of lysosomal enzymes in the
tumor necrotic zone(Weiss, Turner 1978,1980) which promotes necrotic
Infiltration by lysing neighboring cells and thereby releasing additional
lysosomal contents throughout the tumor mass(Autolysis, igure 21).
release of lysosomal
ce
ry
r
ni
hypoxic tumor cell
A:
Section of necrotic/hypoxic
region of the tumor
enzyme
B:
Lysosomal enzyme mediated
hypoxic cell lysis and
connective tissue degradation
11
se
expanded necrotic o ySed cull
region from lysed cell
C:
Lysosome nzyme action results
in:
necrotic zone expansion
tumor vessel opening
tumor cell detachment
Figure 21: Illustration of lysosomal enzyme action on tumor necrosis and
connective tissue degradation.
Is
Thrombin therapy enhances peripheral cell death caused by decreased
perfusion and this, coupled with necrotic infiltration arising from the
diffusion of active lysosmal enzymes throughout the tumor mass, results
in the efficient elimination of the primary tumor from both the inside
out and the outside in. Specifically, upon examination one week after
thrombin therapy it is found that the renal adenocarcinoma tumor volume
has decreased by (53.9 + 0.7)X and the rhabdomyosarcoma tumor volume has
decreased by (43.9+ 0.5)% on average indicating cell anoxia has lead to
substantial tumor necrosis. The itemized results for each tumor
specimen(by tumor radius) are tabulated in table ".
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Renal Adenocarcinoma
Tumor Dameter(cm) Tumor Dameter(cm) . (TD 7)3-(TD 6)3]/(TD 6)3
(t 6 weeks) (t 7 weeks) x 100
mm mmmm m mmmm-m- m m m m mmmmmm-l m------------------------m--mmmm-mmm--
4.5
4.0
3.5
3.2
3.8
3.0
2.9
-39.8%
-57.8%
-43.1%
2.7
2.6 2.0
2.1 1.6
1.5 1.0
1.0 0.75
0.75 0.50
0.50 0.40
-54.5%
-55.8%
-70.4%
-57.8%
-70.4%
-48.8%
Rhabdomyosarcoma
2.5 2.2 -31.9%
1.6
1.2
1.2
1.0
-57.8%
-42.1%
Table 6 Pre-Treatment and Post-Treatment values for Tumor Dameter and
percent change n tumor volume for both tumor systems.
N~ote: T 6 = tumor diameter at 6 weeks post implantaton
TD 7 tumor diameter at 7 weeks post implantation
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A unique feature of thrombin therapy is that it has two factors
which work toward tumor regression; specifically internal necrosis and a
systemic reduction in perfusion leading to furthur internal as well as
peripheral necrosis. Traditional radio and chemo-therapies generally
exert there major cell killing effect over a more focused region namely
the mitotic cells of the tumor periphery leaving most of the tumor cells
viable for regrowth in the future. Expressed graphically(Figure 22) the
effect of thrombin therapy on the wall thickness of the proliferative
tumor cell mass is to cause it to converge to zero; whereas, conventional
therapies only approach a zero thickness of the proliferative tumor cell
mass asymptotically due to cellular regrowth after therapy.
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Figure 22:
DOSE
Qualitative representation of the thickness(r) of the
proliferative tumor cell region as a function of the
cumulative thrombin dose and cumulative present day
chemo/radio-dose.
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5. CONCLUSIONS
5.1 Tumor Vascular Morphpolgy
This examination has provided evidence that a tumor engulfs a
fraction of its own vasculature as it grows. The arguments supporting
this claim are:
(1) Inward radial tumor vessels exist with at least 95% certainty.
(2) Two classes of inward radial tumor vessels are found:
Class 1: Tumor vessels that show no mitotic endothelial cell
impressions and are open-ended.
Class 2: Tumor vessels that show mitotic endothelial cell
impressions and are closed-ended.
The existence of class 1 tumor vessels could be due to the expansion
of the necrotic region of the growing tumor and the concomitant
engulfment of radial tumor vessels. The local secretion of TAF to
stimulate vascular sprouting from venules adjacent to the proliferating
surface of the tumor results in class 2 tumor vessel formation.
Class 1 tumor vessels are present in many micrographs(e.g. Figures
15, 16) where collapsing open-ended radial tumor vessels are observed
adjacent to the tumor necrotic region. The existence of these vessels
could provide a pathway from the tumor interior to the main circulatory
system through which detached cancer cells in the hypoxic region of the
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tumor can travel. Moreover, the existence of Class 1 tumor vessels
supports the hypothesis that an expanding tumor engulfs its own
vasculature.
Class 2 vessels are present among the radial tumor vessels arising
from sprouting vascular buds. Additionally, mitotic endothelial cells
are observed at the tip and periphery of many of these vascular
projections (e.g. Figures 12a, 12b, 13) indicating growth.
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5.2 The Vascular Metastatic Pathway
This examination indicates that Class 1 tumor vessels provide a
pathway for metastasis in the following ways:
(1) With greater then 99% confidence(p ( 0.01) there is a
significant increase in the time to metastasis and
concomitant decrease in the number of open-ended tumor vessels
between treated and control cohorts.
(2) A greater than 95% inverse square correlation is established be
tween N and t in both the treated and control cases. As a
result the blockage of the tumor vascular network via the use
of a direct acting coagulant inhibits metastasis.
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5.3 Thrombin as an Anti-Metastatic and Tumor-Toxic Agent
Evidence suggests that thrombin therapy might be advantageous
because of the synergistic reduction in the peripheral tumor volume and
expansion of the tumor necrotic region which leads to an absolute
convergence to zero for the radius of the proliferative tumor cell layer.
Note that at one week post therapy:
(1) Renal Adenocarcinoma: 53.9 + 0.7% reduction in tumor volume.
(2) Rhabdomyosarcoma: 43.9 + 0.5% reduction in tumor volume.
Therefore, tumor thrombosis acts as a perfusion blocker leading to
the expedient destruction of the primary tumor cells and inhibition of
secondary blood-borne metastases.
For therapy of solid tumors this method has the advantage of
allowing localization of the drug through the entire tumor mass at
therapeutic levels while the periphery is maintained at sub-therapeutic
levels. This concentration gradient is attained by calculating the dose
prescribed by elementary diffusion principles(Appendix D) and then
administering the bolus injection at a designated location. Also, more
than 90% of malignant neoplasms are solid tumors and of those about 75%
are surgically accessible by this mode of therapy.
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5.4 Risks of Thrombin Therapy
The formation of pulmonary emboli could be a risk factor with the
type of therapeutic protocol employed in this study. In practice,
however, a complimentary systemic dose of heparin could be administered
intravenously to protect against the formation of peripheral emboli
should the dose of thrombin entering the tumor periphery exceed
therapeutic levels. However, this is unlikely since the drug will be
diluted in the total blood volume once it has exited the tumor.
Finally, no problems with pulmonary emboli were encountered in 120
animals treated in this study(+ over 380 used in prior studies) and no
harmful side effects of the drug were noted over the duration of the
treated animal's life.
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5.5 RECOMMENDATIONS
This work has provided the baseline evidence for a vascular model
for metastasis. Based on this model a therapy aimed at metastatic
prevention as well as tumor destruction was developed and tested in both
a carcinoma and sarcoma mammalian malignancy. The results of this single
dose therapy were quite successful and now furthur testing of the therapy
as well as the vascular metastatic model remain to be performed in order
that the therapy reach a clinical setting.
First, one needs to investigate the results of a fractionated
thrombin dose study with respect to tumor death and recurrence. In this
study, the delay to metastasis of the animal post treatment was increased
by 100% after only a single thrombin injection to the adenocarcinoma
tumor. Therefore, one would expect to be able to prevent metastasis as
well as the primary tumor with a fractionated therapeutic approach.
Second, in order to establish the therapy's increased efficacy
compared to conventional therapies one would conduct experiments to show
that the thickness of the proliferative tumor cell layer converges to
zero absolutely and not asymptotically. This can be done by
histologically measuring the necrotic diameter and the tumor diameter as
a function of time post thrombin treatment with a single or multiple dose
protocol. The results of this experiment would quantify the effects of
thrombin induced ischemia and necrosis on the primary tumor.
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For multiple fraction treatments the following doses should be used:
fraction Units/injection Total Units
1 U(as given in U
equation 1)
2 .857 U 1.714 U
3 .833 U 2.50 U
4 .800 U 3.20 U
5 .750 U 3.75 U
6 .667 U 4.00 U
Table 7: Listing of doses used in fractionation experiment.
Three days after the administration of the final fraction of
thrombin in each treatment cohort the tumor necrotic region should be
injected with trypan blue, a vital stain which is exclusively absorbed
by non-living cells. The tumor specimen should then be sectioned into 1
mm thick slices and placed on a 5 cm x 5 cm glass slide and mounted on a
light box for viewing with a video camera. Using the image processor the
image of the tumor section can be placed on a numerical grid which fixes
the position of each point of the specimen in space. Using a planometer
the perimeter of both the tumor's necrotic and outer border can be traced
and a calculation of the enclosed cross sectional areas can be performed.
These areas are stored in memory and the procedure is repeated for each
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slice resulting in a three dimensional reconstruction of the solid
tumor's necrotic volume and total tumor volume which can be displayed on
a true three dimensional display system(Genlsco Spacegraph).
Tumor specimens from each fractionated treatment cohort should be
examined in a like manner at 6, 9, 12, 15, 18 and 21 days post thrombin
therapy. The three dimensional volume images of the tumor's necrotic and
viable tissue regions can then be displayed and compared in time post
thrombin therapy. This comparison enables one to examine the efficacy of
the thrombin therapy at various fractionated dose levels and to establish
the best treatment plan for a tumor of a given volume. Finally, in order
to establish the efficacy of the treatment on the prevention of
metastasis one group of animals(15) from each treatment cohort(100 total)
should be returned to their cages and maintained until expiration. The
cause and time of death post tumor implantation should be recorded.
Thrombin can also be used in conjunction with other tumor therapy
modalities. Thrombin therapy induces ischemia(decreased perfusion) which
leads to tumor cell hypoxia and hypoxic cells have increased sensitivity
to high LET radiation(e.g. neutrons, charged particles). Therefore,
irradiation of the tumor with a neutron or charged particle beam after
thrombin therapy will have a higher tumor cell killing effect. Also,
ischemia causes a decrease in the rate of heat exchange via the tumor
circulation and, as a result, heat administered to the tumor in
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hyperthermia treatments would remain localized longer. Consequently, the
hyerthermia therapy would have increased efficacy. In summary, thrombin
therapy could have synergistic action in combination with other forms of
tumor therapy. These possible effects should be investigated.
Finally, one would like to administer thrombin therapy to non-renal
tumor systems, such as hepatic or pulmonary. The establishment of the
therapy's efficacy in the treatment of other malignancies would support
the generalizability of the method for use as a modern day method for
cancer therapy.
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Appendix A
Preparation of Solutions and Materials, Histological Methods
A. Dose of anethesia:
1. Inhalation: Metofane, 50 mg/kg body weight
2. Intramusclar: Sodium Pentobarbital 50 mg/kg of body weight
B. Buffered gluteraldehyde: ph=7.4, Osmolarity=320 osmols, for a final
concentration of 2.5%.
NaH2PO4 oH20
NaHP04 7H20
25% gluteraldehyde in H20
Distilled H20 to make
3.31 gm
33.71 gm
40.0 ml
1000.0 ml
C. Preparation of Mercox: The monomer to initiator weight ratio
Ratio = 100:1
In table A.1 is given the amount of monomer and polymer prepared for
kidney-tumor systems of a given age.
Hardening Time: 20-25 minutes
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System Monomer(gm) Initiator(gm)
Both kidneys normal(control) 8.0 0.08
4 week tumor on left kidney 12.0 0.12
+ normal right kidney
6 week tumor on left kidney 15.0 0.15
+ normal right kidney
8 week tumor on left kidney 20.0 0.20
+ normal right kidney
Table A.1: Listing of monomer and polymer amounts used to cast
kidney-tumor systems of varying tumor ages.
Just prior to the injection of the polymer, the previously measured
monomer and initiator were mixed. The mixture was drawn immediately with
10 cc syringe and injected through an 18 gauge angiocath into the
perfusion line. Note that the polymer and monomer should be measured and
stored in glass beakers before use because plastic materials will react
with these substances at temperatures as low as OOC.
D. KOH for digestion of cast: 20 gm of KOH pellets added to 100 ml of
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distilled H20. Solution normality = 5.6 N.
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Histological Methods
Preparation of Parrafin Sections:
1. Sierra's Fixiative (an aqueous fixiative suitable for subsequent
staining with acidic and basic dyes):
95% ethanol 6 parts
Formalin 3 parts
Glacial Acetic Acid 1 part
2. Procedure:
A. Small pieces(thickness < 5 mm) of tissue are fixed from 2 to 24
hours, depending on size and nature of the tissue.
B. Dehydrate fixed tissue by rinsing in:
1. 95% ethanol --- 3 changes of 1 hour each
2. 100% ethanol -- 2 changes of 1 hour each
3. half 100% ethanol/half chloroform -- until tissue
sinks(approximately one half hour).
4. chloroform ---- overnight or longer.
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C. Infilitrate in 600C oven:
1. half chloroform/half parrafin one half hour
2. parrafin(several changes) 2 hours total
D. Embed in parafin:
1. Put together a stainless steel base and a white plastic
embedding ring.
2. Nearly fill the ring with melted paraffin and immediately place
tissues at bottom(using warm forceps). BE SURE no film has
formed on the surface of the paraffin before tissue is inserted.
3. Holding mold by metal base, partially immerse in cold water
until a film has formed on the surface of the paraffin(blowing
lightly over surface is helpful).
4. When filin is adequate to support water, submerge mold. Leave in
cold water until paraffin block rises to the surface.
(This rapid cooling prevents crystalization of paraffin).
E. Slide preparation:
1. Trim block in the form of a truncated pyramid (apex = cutting
face). Sides of block faces must be parallel.
2. Section at 5-10 microns using a rotatry microtome.
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3. Coat glass slides with a thin film of albumen.
4. Float sections on slides using distilled H20, and then heat on
warming table at 450C.
5. Allow sections to dry thoroughly before staining (usually
overnight).
Hematoxylin and Eosin Stain for Paraffin Sections
A. Deparaffinize sections with xylene 7 min.
B. Hydrate in:
1. half xylene/half 100% ethanol 2 min.
2. 100% ethanol 2 min.
3. 95% ethanol 2 min.
4. 70% ethanol 2 min.
5. 50% ethanol 2 min.
6. distilled H20 2 min.
C. Stain in Ehrlich's Hematoxylin 30 sec.
D. Wash in running H20 until excess stain is no longer visible in wash
water.
'104'
E. Differentiate in:
1. acid alcohol (HCL in 70% ethanol)
2. alkaline alcohol (NH4 0H in 70% ethanol)
rinse only
rinse only or
until section
turns blue.
3. place in 70% ethanol and examine section
F. Eosin 2 min.
G. Dehydrate in alcohol and clear in xylene:
1. 95% ethanol
2. 100% ethanol
3. half 100% ethanol/half xylene
4. xylene(2 changes)
quick rinse
1 min.
2 min.
7 min. total
H. Mount in Permount.
I. If necessary, excess eosin may be removed by soaking off coverslip
in xylene and returning through 100% ethanol to a quick rinse in
95% ethanol, then dehydrating and clearing as in Steps 1-4(G).
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Eosin Stain
Stock Solution: Eosin Y 1 gm
70% ethyl alcohol 1000 ml
Glacial Acetic Acid 5 ml
Working Solution: Dilute stock solution with an equal volume of 70%
alcohol and add 2-3 drops of acetic acid(stock).
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Appendix B
List of Materials and their Manufacturing Companies
Ammonium Hydroxide: Stock
Fisher Scientific Co., Fair Lawn, N.J. 07410
Aluminum Stubs: 15 mm diameter, 10 mm high
Research Ind., Inc., Burlington, Vermont 05401
Angiocath: 18 gauge, 1.5 inch
Desert Co., Sandy Utah 84070
Autoclips: 9 mm, non-sterile
Clay Adams, Parsippany, N.J. 07054
Chloroform: Stock
Fisher Scientific Co., Fair Lawn, N.J. 07410
Copper grids: Carbon stabilized
Ted Paella, Tustin, Ca. 92680
Ehrlich's Hemotoxylin: Stock
Fisher Scientific Co., Fair Lawn, N.J. 07410
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Eosin Y: Stock
Fisher Scientific Co., Fair Lawn, N.J. 07410
Ethanol: Pure ethyl alcohol, dehydrated
U.S. Industrial Chemical, N.Y., N.Y.
Formaldehyde: Stock
Fisher Scientific Co., Fair Lawn, N.J. 07410
Glacial Acetic Acid: Stock
Fisher Scientific Co., Fair Lawn, N.J. 07410
Gluteraldehyde: 25% in H20, Practical grade
J.T. Baker Chemical Co., Phillipsburg, N.J. 08865
Heparine: Heparine Sodium, Lab grade
Fisher Scientific Co., Fair Lawn, N.J. 07410
Hydrochloric Acid: Stock
Fisher S;cientific Co., Fair Lawn, N.J. 07410
Light Microscope: Zeiss Model# 47 79 01 9901
D-7082 Oberkochen, West Germany
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Metofane: 50 mg/cc; Inhalation Anesthetic
Pitman-Moore, Inc., Washington Crossing, N.J. 08560
Mercox: Blue(Methyl Methacrylate)
Ladd Research Industries, Inc., Burlington, Vermont 05401
Parrafin: Solid(White)
Fisher Scientific Co., Fair Lawn, N.J. 07410
Pottasium Hydroxide: Dry solid pellets
MCB Manuf., Cincinnati, Ohio 45212
Rat: Wistar-Lewis, Female, 300 gms.
Charles River Co., Ma. 02139
Rat: Wag-Rij, Female, 200 gms.
Lawrence Berkeley Laboratory, Berkeley, Ca. 94720
Renal adenocarcinoma: Tumor System
Dr. Richard Babayan, Boston City Hospital, Boston, Ma.
Dr. Alan C. Nelson, MIT Cambridge, Ma.
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Rhabdomyosarcoma: Tumor System
Dr. Stan Curtis, Lawrence Berkeley Laboratory, Berkeley, Ca. 94720
RPMI growth medium: #1640, with 25 mM Hepes
M.A. Bioproducts, Walkersville, Maryland 21793
Saline: 0.85%, Sterile, physiological pH
Fisher Scientific Co., Fair Lawn, N.J. 07410
Scanning Electron Microscope: DS-130
ISI, Mountain View, Ca.
Silver colloid:
Ted Pella Inc., Tustin, CA. 92680
Sodium Pentobarbital: Anesthetic
Pitman-Moore, Inc., Washington Crossing, NJ 08560
Sodium Phosphate: Dibasic, Heptahydrate
Fisher Scientific Co., Fair Lawn, NJ 07410
Sodium Phosphate: Monobasic, Crystals
MCB Manufactor, Cincinnati, Ohio 45212
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Sputter Coater: SEM coating unit E51000
Polaron Instruments Inc.
Sutures: Dexon 3-0
Davis-Geck, P.R. 00701
Thrombin: USP Bovine origin
Parke-Davis, Morris Plains, NJ 07950
Water: Distilled
Fisher Scientific Co., Fair Lawn, NJ 07410
Xylene: Stock
Fisher Scientific Co., Fair Lawn, NJ 07410
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Appendix C
The Structure and Physiological Role of Thrombin:
Thrombin is a multifunctional enzyme, which may react specifically
with several proteins and cells(via receptors) as well as nonspecifically
with the surfaces(e.g.
molecules(Machovich, 1981;
mucopolysaccharides)
Fenton, 1981). I
or with other
ts main targets are
summarized in figure C.1.
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Figure C.1: Biological functions of thrombin.
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The function of thrombin n the maintenance of hemostatic balance is
attained by several biological reactions. According to modern day
knowledge, ts main function is the catalysis of the fibrinogen-fibrin
conversion. The fibrin thrombus formed, however, is not the final form
of a thrombus. In nearly all cases, aggregates of platlets are found in
the thrombus. Furthermore, the size and stability of the clot is further
modified by another enzyme, Factor XIIIa. Thrombin plays a major role in
above-mentioned two processes as well: its binding to platlets initiates
changes in the cell metabolism and its reaction with Factor XIII results
in the activation of the proenzyme, fibrinogen.
In addition, thrombin binds to endothelial cells with high affinity,
inducing prostacyclin release and several other biochemical reactions.
Thrombin regulates its own concentration through reactions with
prothrombin, Factor V, Factor VII, and Protein C. Besides these, more
than ten other biological functions of thrombin are known, although their
importance in the maintenance of hemostatic balance, Is under
investigation.
Thrombin s a highly specific proteolytic enzyme. It is a serine
protease with trypsin-like specificity. The primary structures of the
bovine and human enzymes have been determined(Blomback, 1969; Iwanaga,
1964) and are shown In figure C.2. The active site residues actually
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serine(#205).
catalysis.
A Chain
1
Hum;ln
Bovine
These three residues interact during the process of
TFGSGEANCGLRPLFEKKSLENKTERELLESYIDGR
TSEDHFEPFFNEKTFGAGEADCGLRPLFEKKQVQDETQKFLFESYIEGR
B Chain
1
Human
BoN inc
70
IVEGSNAEIGMSPWQVMLFRKSPQELLCGASLISNRWVLTAAHCLLYPPWNKNFTENDLLVRIGKHSRTR
IVEGQDAEVGLSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTVDDLLVRIGKHSRTR
YERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAPSDFIHPVCLPNRETAASLLGAGYKGRVTG
YERKVEKISMLDKIYIHPRYNWKENLDRDIALLKLKRPIELSDFIHPVCLPDKQTAAKLLHAGFKGRVTG
141
140
210
YGNLKSTVTADVGKGQPSVLQVVNLALVQRPVCKDSTRIRITDNMFCAGYKPDEGKRGDACEGDSGGPFV
WGNRRETWTTSVAEVQPSVLQVVNLPLVERPVCKASTRIRITNDMFCAGYKPGEGKRGDACEGDSGGPFV
211
MKSPFNNRWYQMGIVSWGEGCDRDGKYGFYTHVFRLKKWIQKVIDQFGE
MKSPYNNBWYQMGIVSWGEGCDRNGKYGFYTHVFRLKKWIQKVIDRLGS
Ala A Gin
Arg R Glu
An N GIl
Ap
Cy%
D Hi% H
C
Q Leu L Ser
I L. s K Thr
G Met NM Trp
Ile I Pro P Val
Figure C.2: Structure of human and bovine alpha thrombin.
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Appendix D
Thrombin Dose Calculation
The thrombin dose administered is a function of tumor radius and has
been calculated. It is assumed that the injected dose of thrombin
diffuses isotropically through tissue and can be modeled as an
instantaneous point source. Under these conditions the concentration of
thrombin as a function of radius(r) and time(t) is given by the solution
to the time dependent diffusion equation:
V2C(r,t) = (D)-ldC(r,t)/dt (D.1)
where:
r = radius in cm (point of injection[r=O])
t = time in sec (time of injection, to= O)
D = 1.8 E-5 cm2 /sec
(thrombin diffusion coefficient in tissue),(Choi,1961)
The thrombin injection initially occupies a small volume of radius, a,
whose concentration is given by:
C(r,t) = CO for 0 < r < a
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C(r,t) = 0 for r > a
Using these boundary conditions we find the solution to equation (D.1):
C(r,t) = [U/8(rDt)1.5)ef-r2/4Dt(1+(r 2/Dt-6)a2/4ODt}] (D.2)
where U = 4/3ra 3 Co
In the limit as a approaches zero and U is kept constant(i.e Co
increases), equation(D.2) reduces to a point source function:
C(r,t) = (U/8(rDt)1.5)e(-r2/4Dt) (D.3)
Rearranging,
U = C(r,t)8(iDt) 1 .5 e(r2/4Dt) (D.4)
At t = tmax = r2/6D and C(r,t) = Ctherapeutic(rt) = 2 units/ml
equation D.4 becomes:
U = Ctherapeutic(r,t)8(rer 2)1 e5 (D.5)
or
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*U = 8(2 units/ml)*(rer 2) 1 .5 (D.6)
* Note: The value of U calculated by equation D.6 will overestimate the
actual value by the fraction (Tumor volume/Vascular volume) because the
calculation above derives a value for U based on the assumption that the
drug is diffusing through a sphere of blood; whereas the tumor tissue is
comprised of cells, blood, connective tissues, and air .space.
Therefore the most accurate value for U is given by:
U'= 8(2 units/ml).(rer2)1 .5 (vascular volume/1.333r3)
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c Thrombin Dose Calculation
c Computer Routine
C
c
c This routine is designed to calculate the number of units
c thrombin one should administer to the tumor necrotic region
c such that at time, tmax the dose of thrombin will have reached
c therapeutic levels throughout the entire tumor mass.
c
real*4 re, units, tmax, vv
alpha = 399.3
beta - .3888
print *, ' '
print * 'Enter tumor radius(in cm):
print * ' 
Accept 10, re
10 format(fl0.4)
print *, ' '
print *, 'Enter vascular volume(in ml):
print*, ' '
'1181
Accept 20, vv
20 format(flO.4)
units = (alpha) * (vv/(1.333*re**3)) * re**3
print *, ' The number of thrombin units needed = ', units
tmax = (re**2)/beta
print *, 'tmax = ', tmax
stop
end
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